Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 21,010 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune System Disorders Clear all
Completed Phase 1 Interventional

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

NCT02028403
View directory record Official record
Conditions
HIV Infections
Interventions
BMS-936559, Placebo for BMS-936559
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2021 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional

DNA Vaccine for Ragweed Allergic Adults

NCT00346086
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
AIC (Amb a 1 Immunostimulatory Conjugate)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 31, 2026, 5:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue

NCT06132386
View directory record Official record
Conditions
HIV Infections, Aging
Interventions
biopsy
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 5:27 PM EDT
Not listed Phase 2 Interventional

A Study of the Safety, Efficacy and Tolerability of Nexvax-2 in Patients With Celiac Disease (CeD)

NCT03644069
View directory record Official record
Conditions
Celiac Disease, Celiac, Intestinal Disease, Malabsorption Syndromes, Gastrointestinal Disease, Digestive System Disease, Gluten Sensitivity, Autoimmune Diseases
Interventions
Nexvax2, Placebo
Biological
Lead sponsor
ImmusanT, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Walnut Creek, California • Stamford, Connecticut • Lighthouse PT, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease

NCT00862641
View directory record Official record
Conditions
Asthma, Coronary Artery Disease, Pulmonary Disease, Chronic Obstructive
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
1,009 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
48
States / cities
Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 31, 2026, 5:27 PM EDT
Completed No phase listed Observational

Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis

NCT00001541
View directory record Official record
Conditions
Inflammation, Vasculitis, Wegener's Granulomatosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 5:27 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Quantitative Imaging and Proton Spectroscopy in Multiple Sclerosis

NCT01226654
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
7 Years to 110 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1991 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 31, 2026, 5:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Autoantibodies to Gastric Parietal Cells in Rheumatoid Arthritis Patients

NCT01876329
View directory record Official record
Conditions
Vitamin B12 Deficiency
Interventions
Not listed
Lead sponsor
Keesler Air Force Base Medical Center
Federal
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Keesler Air Force Base, Mississippi
Source: ClinicalTrials.gov public record
Updated May 29, 2015 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

NCT00007995
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
filgrastim, recombinant interferon alfa, sargramostim, busulfan, cyclophosphamide, melphalan, autologous bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Herbert Irving Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effects of Interleukin-12 (rhIL-12) in HIV-Positive Patients With CD4 Cell Counts Less Than 50 Cells/mm3 or 300-500 Cells/mm3

NCT00000857
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-12
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
16
States / cities
Los Angeles, California • Palo Alto, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy Volunteers

NCT02085473
View directory record Official record
Conditions
Asthma, Healthy Subjects or Volunteers
Interventions
Tralokinumab 300 mg
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
19 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease

NCT02195869
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Ibrutinib
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
10
States / cities
Duarte, California • San Francisco, California • Stanford, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 31, 2026, 5:27 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Study of Chronic Lymphocytic Leukemia Families

NCT00503256
View directory record Official record
Conditions
Leukemia
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
4,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

NCT02637856
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Ocrelizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
67
States / cities
Cullman, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Not applicable Interventional

Photobiomodulation Therapy in Persons With Multiple Sclerosis

NCT03691766
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Photobiomodulation Therapy, Placebo
Other
Lead sponsor
Marquette University
Other
Eligibility
20 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 4 Interventional Results available

Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection

NCT02095951
View directory record Official record
Conditions
Leukemia, Lymphoma, Blood Disorders, Solid Tumors
Interventions
Ethanol lock therapy (ELT)
Drug
Lead sponsor
Children's Hospital of Michigan
Other
Eligibility
6 Months to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 31, 2026, 5:27 PM EDT
Not yet recruiting Phase 1 Interventional

Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV

NCT06233331
View directory record Official record
Conditions
Human Papilloma Virus, Human Immunodeficiency Virus, Anal Intraepithelial Neoplasia, High-Grade Squamous Intraepithelial Lesions
Interventions
Dose Level 1 ACU-D1 ointment, Dose Level 2 ACU-D1 ointment, Dose Level 3 ACU-D1 ointment, Vulvar/ Perianal Biopsy
Drug · Procedure
Lead sponsor
Emory University
Other
Eligibility
21 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Recruiting No phase listed Observational

Smoldering Inflammation in MS

NCT06591429
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Radiotracer [11C]-CS1P1, Radiotracer [11C]-DPA-713, anti-CD20 MS treatment, Radiotracer [12F]-FDG
Radiation · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

NCT07439653
View directory record Official record
Conditions
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Interventions
TORL-5-700, TORL-5-700 at MTD/RP2D, TORL-5-700 at MTD/RP2D in combination with another agent
Drug
Lead sponsor
TORL Biotherapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Fullerton, California • Los Alamitos, California • Santa Monica, California + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Active, not recruiting Phase 2 Interventional

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia

NCT05734495
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Pirtobrutinib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

NCT00430495
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 31, 2026, 5:27 PM EDT
Withdrawn Not applicable Interventional

Initiation of Chronic Asthma Care Regimens in the Pediatric Emergency Department

NCT00388739
View directory record Official record
Conditions
Asthma
Interventions
Intervention: Budesonide, Usual care: albuterol + systemic steroids
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT00398112
View directory record Official record
Conditions
B-cell Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
Interventions
sunitinib malate, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2014 · Synced Oct 31, 2026, 5:27 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Oral Warts in HIV+ Patients

NCT00454181
View directory record Official record
Conditions
Papillomatosis, HIV Infections
Interventions
Interferon-alpha, placebo
Drug · Other
Lead sponsor
Ainos, Inc. (f/k/a Amarillo Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
12
States / cities
San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2011 · Synced Oct 31, 2026, 5:27 PM EDT